PR Newswire Tech#pr
Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrometranslating…
Factuality: 70/100USACision
MZ‑1866 Phase 1/2 UNITE Study is now more than 50% enrolled SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the U.S. Food…